| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1010471149 |
| P356 | DOI | 10.1007/BF00874423 |
| P8608 | Fatcat ID | release_6qaefhcgwffwpi5l7oxlfoad74 |
| P698 | PubMed publication ID | 8157467 |
| P2093 | author name string | M Aapro | |
| P2860 | cites work | The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer | Q36468076 |
| How should nausea be assessed in patients receiving chemotherapy? | Q37018135 | ||
| Controlling emesis related to cancer therapy | Q37084146 | ||
| Methodology of antiemetic trials: a review | Q37764625 | ||
| The symptomatic control of cytostatic drug-induced emesis. A recent history and review | Q37893441 | ||
| Cancer therapy, vomiting, and antiemetics. | Q37905205 | ||
| Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide | Q38536390 | ||
| Psychological response to breast cancer: effect on outcome | Q39568687 | ||
| Delta-9-Tetrahydrocannabinol in Cancer Chemotherapy: Research Problems and Issues | Q40135420 | ||
| The epidemiologic evidence for a relationship between social support and health | Q40148594 | ||
| Methodology in behavioral and psychosocial cancer research. The assessment of nausea and vomiting. Past problems, current issues and suggestions for future research. | Q40238806 | ||
| The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy | Q40782212 | ||
| Psychological response to cancer and survival | Q41187358 | ||
| An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy | Q41206449 | ||
| Dose-ranging antiemetic trial of high-dose oral metoclopramide | Q41232328 | ||
| Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial | Q41305280 | ||
| Quality of life during chemotherapy for small cell lung cancer: assessment and use of a daily diary card in a randomized trial | Q41963292 | ||
| A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group | Q44495445 | ||
| The status of blacks in medicine. Philosophical and ethical dilemmas for the 1980s | Q46349397 | ||
| Susceptibility to motion sickness and the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy | Q48629928 | ||
| Nonpharmacologic factors in the development of posttreatment nausea with adjuvant chemotherapy for breast cancer. | Q51190741 | ||
| Anxiety and drug taste as predictors of anticipatory nausea in cancer chemotherapy. | Q51213416 | ||
| Antiemetic efficacy of droperidol or metoclopramide combined with dexamethasone and diphenhydramine. Randomized open parallel study. | Q51719059 | ||
| Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Re | Q51746449 | ||
| Mental attitudes to cancer: an additional prognostic factor. | Q52083412 | ||
| Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. | Q52612776 | ||
| Antiemetic studies: a methodological discussion. | Q52641976 | ||
| On the receiving end--patient perception of the side-effects of cancer chemotherapy. | Q55062718 | ||
| Patients' and nurses' perceptions of symptom distress in cancer | Q56603175 | ||
| ANTIEMETIC DRUG COMBINATIONS IN ADVANCED CANCER | Q60716091 | ||
| Short report: Emesis during past pregnancy: A new prognostic factor in chemotherapy-induced emesis | Q61917336 | ||
| Are all 5-HT3 receptor antagonists the same? | Q67491841 | ||
| Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy | Q68412436 | ||
| A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group | Q68478567 | ||
| The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis | Q68478571 | ||
| A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group | Q68478575 | ||
| Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group | Q68478579 | ||
| Assessment of nausea | Q68781175 | ||
| Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation | Q69105467 | ||
| Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin | Q69291980 | ||
| GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis | Q69300253 | ||
| Amelioration of chemotherapy-induced thrombocytopenia by GM-CSF: apparent dose and schedule dependency | Q69536625 | ||
| Myths of antiemetic administration | Q69597704 | ||
| Measurement of nausea | Q69724647 | ||
| A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer | Q69900263 | ||
| Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research | Q69921477 | ||
| Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting | Q70177918 | ||
| Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion | Q71234818 | ||
| High-dose dexamethasone for prevention of cis-platin-induced vomiting | Q72525430 | ||
| Behavioral Treatment for the Anticipatory Nausea and Vomiting Induced by Cancer Chemotherapy | Q72540281 | ||
| Comparative Trial of the Antiemetic Effects of THC and Haloperidol | Q72912448 | ||
| Cannabis and cancer chemotherapy. A comparison of oral delta-9-thc and prochlorperazine | Q72935600 | ||
| Making chemotherapy easier | Q95816409 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 243-253 | |
| P577 | publication date | 1993-11-01 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | Methodological issues in antiemetic studies | |
| P478 | volume | 11 |
| Q44925317 | 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy |
| Q36330661 | A systematic review of methodologies, endpoints, and outcome measures in randomized trials of radiation therapy-induced nausea and vomiting |
| Q35984417 | Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update. |
| Q35681839 | Factors influencing the choice of 5-HT3-receptor antagonist antiemetics: focus on elderly cancer patients |
| Q98784317 | Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety |
| Q40397083 | Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy |
| Q35566262 | Pharmacology of Antiemetics |
Search more.